Nanoparticle Technologies for Cancer Therapy

  • Frank Alexis
  • Eric M. Pridgen
  • Robert Langer
  • Omid C. Farokhzad
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 197)

Abstract

Nanoparticles as drug delivery systems enable unique approaches for cancer treatment. Over the last two decades, a large number of nanoparticle delivery systems have been developed for cancer therapy, including organic and inorganic materials. Many liposomal, polymer–drug conjugates, and micellar formulations are part of the state of the art in the clinics, and an even greater number of nanoparticle platforms are currently in the preclinical stages of development. More recently developed nanoparticles are demonstrating the potential sophistication of these delivery systems by incorporating multifunctional capabilities and targeting strategies in an effort to increase the efficacy of these systems against the most difficult cancer challenges, including drug resistance and metastatic disease. In this chapter, we will review the available preclinical and clinical nanoparticle technology platforms and their impact for cancer therapy.

Keywords

Nanoparticle Drug delivery Targeted Metastatic cancer Cancer therapy 

Abbreviations

BBB

Blood–brain barrier

DSPC

1,2-Distearoyl-glycero-3-phosphocholine

DSPE

1,2-Distearoyl-sn-glycero-3-phosphoethanolamine

EggPG

Egg yolk phosphatidylglycerol

EPR

Enhanced Permeability and Retention effect

FDA

Food and Drug Administration

HPMA

N-(2-Hydroxypropyl)methacrylamide

HSPC

Hydrogenated phosphatidylcholine from soybean lecithin

LPS

Lipopolysaccharide

MTD

Maximum tolerated dose

NCI

National Cancer Institute

NIR

Near infrared

NSCL cancer

Non-small-cell lung cancer

PAMAM

Polyamidoamine

PDLLA

Poly-dl-lactic acid

PEG

Polyethylenglycol

PLA

Polylactic acid

PLA2

Phospholipase A2

PLGA

Poly(lactic-co-glycolic acid)

SEM

Scanning electron microscope

References

  1. Adler HI, Fisher WD, Cohen A, Hardigree AA (1967) Miniature Escherichia coli cells deficient in DNA. Proc Natl Acad Sci USA 57:321–326PubMedGoogle Scholar
  2. Ahmed F, Pakunlu RI, Srinivas G, Brannan A, Bates F, Klein ML, Minko T, Discher DE (2006) Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation. Mol Pharm 3:340–350PubMedGoogle Scholar
  3. Al-Jamal WT, Al-Jamal KT, Bomans PH, Frederik PM, Kostarelos K (2008) Functionalized-quantum-dot-liposome hybrids as multimodal nanoparticles for cancer. Small 4:1406–1415PubMedGoogle Scholar
  4. Alexis F, Basto P, Levy-Nissenbaum E, Radovic-Moreno AF, Zhang L, Pridgen E, Wang AZ, Marein SL, Westerhof K, Molnar LK, Farokhzad OC (2008a) HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. ChemMedChem 3:1839–1843PubMedCentralPubMedGoogle Scholar
  5. Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008b) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505–515PubMedCentralPubMedGoogle Scholar
  6. Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC (2008c) New frontiers in nanotechnology for cancer treatment. Urol Oncol 26:74–85PubMedGoogle Scholar
  7. Aliabadi HM, Shahin M, Brocks DR, Lavasanifar A (2008) Disposition of drugs in block copolymer micelle delivery systems: from discovery to recovery. Clin Pharmacokinet 47:619–634PubMedGoogle Scholar
  8. Andresen TL, Davidsen J, Begtrup M, Mouritsen OG, Jorgensen K (2004) Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs. J Med Chem 47:1694–1703PubMedGoogle Scholar
  9. Andresen TL, Jensen SS, Kaasgaard T, Jorgensen K (2005) Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2. Curr Drug Deliv 2:353–362PubMedGoogle Scholar
  10. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, Holtsberg FW, Bomalaski JS, Clark MA, Savaraj N, Feun LG, Logan TF (2005) Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 23:7660–7668PubMedGoogle Scholar
  11. Bagalkot V, Farokhzad OC, Langer R, Jon S (2006) An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl 45:8149–8152PubMedGoogle Scholar
  12. Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, Farokhzad OC (2007) Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett 7:3065–3070PubMedGoogle Scholar
  13. Bangham AD, Standish MM, Watkins JC (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13:238–252PubMedGoogle Scholar
  14. Bareford LM, Swaan PW (2007) Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 59:748–758PubMedCentralPubMedGoogle Scholar
  15. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME (2007) Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 104:15549–15554PubMedGoogle Scholar
  16. Bertin PA, Gibbs JM, Shen CK, Thaxton CS, Russin WA, Mirkin CA, Nguyen ST (2006) Multifunctional polymeric nanoparticles from diverse bioactive agents. J Am Chem Soc 128:4168–4169PubMedGoogle Scholar
  17. Bierie B, Moses HL (2006) Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6:506–520PubMedGoogle Scholar
  18. Bissell MJ, Labarge MA (2005) Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 7:17–23PubMedCentralPubMedGoogle Scholar
  19. Boddy AV, Plummer ER, Todd R, Sludden J, Griffin M, Robson L, Cassidy J, Bissett D, Bernareggi A, Verrill MW, Calvert AH (2005) A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res 11:7834–7840PubMedGoogle Scholar
  20. Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649–1659PubMedGoogle Scholar
  21. Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54:631–651PubMedGoogle Scholar
  22. Cairns R, Papandreou I, Denko N (2006) Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 4:61–70PubMedGoogle Scholar
  23. Campone M, Rademaker-Lakhai JM, Bennouna J, Howell SB, Nowotnik DP, Beijnen JH, Schellens JH (2007) Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother Pharmacol 60:523–533PubMedGoogle Scholar
  24. Castor TP (2005) Phospholipid nanosomes. Curr Drug Deliv 2:329–340PubMedGoogle Scholar
  25. Cedervall T, Lynch I, Foy M, Berggard T, Donnelly SC, Cagney G, Linse S, Dawson KA (2007a) Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew Chem Int Ed Engl 46:5754–5756PubMedGoogle Scholar
  26. Cedervall T, Lynch I, Lindman S, Berggard T, Thulin E, Nilsson H, Dawson KA, Linse S (2007b) Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA 104:2050–2055PubMedGoogle Scholar
  27. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572PubMedGoogle Scholar
  28. Chan JM, Zhang L, Yuet KP, Liao G, Rhee JW, Langer R, Farokhzad OC (2009) PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 30:1627–1634PubMedGoogle Scholar
  29. Chen Y, Huang L (2008) Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy. Expert Opin Drug Deliv 5:1301–1311PubMedGoogle Scholar
  30. Cheng Y, CS A, Meyers JD, Panagopoulos I, Fei B, Burda C (2008) Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J Am Chem Soc 130:10643–10647PubMedCentralPubMedGoogle Scholar
  31. Chithrani BD, Chan WC (2007) Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett 7:1542–1550PubMedGoogle Scholar
  32. Chithrani BD, Ghazani AA, Chan WC (2006) Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 6:662–668PubMedGoogle Scholar
  33. Couvreur P, Kante B, Roland M, Speiser P (1979) Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum. J Pharm Sci 68:1521–1524PubMedGoogle Scholar
  34. Cullis PR, Chonn A (1998) Recent advances in liposome technologies and their applications for systemic gene delivery. Adv Drug Deliv Rev 30:73–83PubMedGoogle Scholar
  35. Davis M (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6:659–668PubMedGoogle Scholar
  36. Davis ME, Brewster ME (2004) Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 3:1023–1035PubMedGoogle Scholar
  37. Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7:771–782PubMedGoogle Scholar
  38. Decuzzi P, Ferrari M (2006) The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials 27:5307–5314PubMedGoogle Scholar
  39. Decuzzi P, Ferrari M (2008) Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials 29:377–384PubMedGoogle Scholar
  40. Decuzzi P, Gentile F, Granaldi A, Curcio A, Causa F, Indolfi C, Netti P, Ferrari M (2007) Flow chamber analysis of size effects in the adhesion of spherical particles. Int J Nanomedicine 2:689–696PubMedCentralPubMedGoogle Scholar
  41. Decuzzi P, Lee S, Bhushan B, Ferrari M (2005) A theoretical model for the margination of particles within blood vessels. Ann Biomed Eng 33:179–190PubMedGoogle Scholar
  42. Decuzzi P, Pasqualini R, Arap W, Ferrari M (2009) Intravascular delivery of particulate systems: does geometry really matter? Pharm Res 26:235–243PubMedGoogle Scholar
  43. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–1324PubMedGoogle Scholar
  44. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ (2008) Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 105:17356–17361PubMedGoogle Scholar
  45. Discher BM, Won YY, Ege DS, Lee JC, Bates FS, Discher DE, Hammer DA (1999) Polymersomes: tough vesicles made from diblock copolymers. Science 284:1143–1146PubMedGoogle Scholar
  46. Euliss LE, DuPont JA, Gratton S, DeSimone J (2006) Imparting size, shape, and composition control of materials for nanomedicine. Chem Soc Rev 35:1095–1104PubMedGoogle Scholar
  47. Fan H (2008) Nanocrystal-micelle: synthesis, self-assembly and application. Chem Commun (Camb) 28:1383–1394Google Scholar
  48. Farokhzad OC (2008) Nanotechnology for drug delivery: the perfect partnership. Expert Opin Drug Deliv 5:927–929PubMedGoogle Scholar
  49. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R (2006a) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103:6315–6320PubMedGoogle Scholar
  50. Farokhzad OC, Dimitrakov JD, Karp JM, Khademhosseini A, Freeman MR, Langer R (2006b) Drug delivery systems in urology–getting "smarter". Urology 68:463–469PubMedCentralPubMedGoogle Scholar
  51. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R (2004) Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64:7668–7672PubMedGoogle Scholar
  52. Farokhzad OC, Karp JM, Langer R (2006c) Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv 3:311–324PubMedGoogle Scholar
  53. Farokhzad OC, Langer R (2006) Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 58:1456–1459PubMedGoogle Scholar
  54. Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS Nano 3:16–20PubMedGoogle Scholar
  55. Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5: 161–171PubMedGoogle Scholar
  56. Ferrari M (2008) Nanogeometry: beyond drug delivery. Nat Nanotechnol 3:131–132PubMedGoogle Scholar
  57. Fesik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5:876–885PubMedGoogle Scholar
  58. Fidler IJ (1995) Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 87:1588–1592PubMedGoogle Scholar
  59. Fidler IJ (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3:453–458PubMedGoogle Scholar
  60. Florence AT, Hussain N (2001) Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv Drug Deliv Rev 50(Suppl 1):S69–S89PubMedGoogle Scholar
  61. Fox JL (2000) Researchers discuss NIH's nanotechnology initiative. Nat Biotechnol 18:821PubMedGoogle Scholar
  62. Freitas RA Jr (2005) What is nanomedicine? Dis Mon 51:325–341PubMedGoogle Scholar
  63. Galon J, Fridman WH, Pages F (2007) The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 67:1883–1886PubMedGoogle Scholar
  64. Gao J, Liang G, Cheung JS, Pan Y, Kuang Y, Zhao F, Zhang B, Zhang X, Wu EX, Xu B (2008) Multifunctional yolk-shell nanoparticles: a potential MRI contrast and anticancer agent. J Am Chem Soc 130:11828–11833PubMedGoogle Scholar
  65. Gao K, Huang L (2008) Nonviral methods for siRNA delivery. Mol Pharm 6:651–658Google Scholar
  66. Gary DJ, Puri N, Won YY (2007) Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release 121:64–73PubMedGoogle Scholar
  67. Gentile F, Chiappini C, Fine D, Bhavane RC, Peluccio MS, Cheng MM, Liu X, Ferrari M, Decuzzi P (2008a) The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. J Biomech 41:2312–2318PubMedGoogle Scholar
  68. Gentile F, Curcio A, Indolfi C, Ferrari M, Decuzzi P (2008b) The margination propensity of spherical particles for vascular targeting in the microcirculation. J Nanobiotechnology 6:9PubMedCentralPubMedGoogle Scholar
  69. Gradishar WJ (2006) Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7:1041–1053PubMedGoogle Scholar
  70. Gratton SE, Napier ME, Ropp PA, Tian S, DeSimone JM (2008a) Microfabricated particles for engineered drug therapies: elucidation into the mechanisms of cellular internalization of PRINT particles. Pharm Res 25:2845–2852PubMedCentralPubMedGoogle Scholar
  71. Gratton SE, Pohlhaus PD, Lee J, Guo J, Cho MJ, Desimone JM (2007) Nanofabricated particles for engineered drug therapies: a preliminary biodistribution study of PRINT nanoparticles. J Control Release 121:10–18PubMedCentralPubMedGoogle Scholar
  72. Gratton SE, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, DeSimone JM (2008b) The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 105:11613–11618PubMedGoogle Scholar
  73. Greco F, Vicent MJ (2008) Polymer–drug conjugates: current status and future trends. Front Biosci 13:2744–2756PubMedGoogle Scholar
  74. Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Muller RH (2000) 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 18:301–313PubMedGoogle Scholar
  75. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R (1994) Biodegradable long-circulating polymeric nanospheres. Science 263:1600–1603PubMedGoogle Scholar
  76. Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, Langer R, Farokhzad OC (2008) Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 105:2586–2591PubMedGoogle Scholar
  77. Guo X, MacKay JA, Szoka FC Jr (2003) Mechanism of pH-triggered collapse of phosphatidylethanolamine liposomes stabilized by an ortho ester polyethyleneglycol lipid. Biophys J 84:1784–1795PubMedCentralPubMedGoogle Scholar
  78. Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, Ueno H, Muro K, Yamada Y, Okusaka T, Shirao K, Shimada Y, Nakahama H, Matsumura Y (2007) A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer 97:170–176PubMedCentralPubMedGoogle Scholar
  79. Hawkins MJ, Soon-Shiong P, Desai N (2008) Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60:876–885PubMedGoogle Scholar
  80. Heath TD, Fraley RT, Papahdjopoulos D (1980) Antibody targeting of liposomes: cell specificity obtained by conjugation of F(ab')2 to vesicle surface. Science 210:539–541PubMedGoogle Scholar
  81. Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME (2007) Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 104:5715–5721PubMedGoogle Scholar
  82. Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, Price RE, Hazle JD, Halas NJ, West JL (2003) Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 100:13549–13554PubMedGoogle Scholar
  83. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607–4612PubMedGoogle Scholar
  84. Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI (2007) Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res 13:5855–5861PubMedGoogle Scholar
  85. Jain KK (2008) Nanomedicine: application of nanobiotechnology in medical practice. Med Princ Pract 17:89–101PubMedGoogle Scholar
  86. James JS (1995a) DOXIL approved by FDA. AIDS Patient Care 9:306Google Scholar
  87. James JS (1995b) DOXIL approved for KS. AIDS Treat News 236:6Google Scholar
  88. Jensen SS, Andresen TL, Davidsen J, Hoyrup P, Shnyder SD, Bibby MC, Gill JH, Jorgensen K (2004) Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. Mol Cancer Ther 3:1451–1458PubMedGoogle Scholar
  89. Jiang W, Kim BY, Rutka JT, Chan WC (2007) Advances and challenges of nanotechnology-based drug delivery systems. Expert Opin Drug Deliv 4:621–633PubMedGoogle Scholar
  90. Johannsen M, Gneveckow U, Eckelt L, Feussner A, Waldofner N, Scholz R, Deger S, Wust P, Loening SA, Jordan A (2005) Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int J Hyperthermia 21:637–647PubMedGoogle Scholar
  91. Johannsen M, Gneveckow U, Thiesen B, Taymoorian K, Cho CH, Waldofner N, Scholz R, Jordan A, Loening SA, Wust P (2007) Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution. Eur Urol 52:1653–1661PubMedGoogle Scholar
  92. Jorgensen K, Davidsen J, Mouritsen OG (2002) Biophysical mechanisms of phospholipase A2 activation and their use in liposome-based drug delivery. FEBS Lett 531:23–27PubMedGoogle Scholar
  93. Juliano R, Alam MR, Dixit V, Kang H (2008) Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 36:4158–4171PubMedCentralPubMedGoogle Scholar
  94. Kaneda Y (2000) Virosomes: evolution of the liposome as a targeted drug delivery system. Adv Drug Deliv Rev 43:197–205PubMedGoogle Scholar
  95. Kawasaki ES, Player A (2005) Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine 1:101–109PubMedGoogle Scholar
  96. Kelly JY, DeSimone JM (2008) Shape-specific, monodisperse nano-molding of protein particles. J Am Chem Soc 130:5438–5439PubMedGoogle Scholar
  97. Kester M, Heakal Y, Fox T, Sharma A, Robertson GP, Morgan TT, Altinoglu EI, Tabakovic A, Parette MR, Rouse S, Ruiz-Velasco V, Adair JH (2008) Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano Lett 8:4116–4121PubMedCentralPubMedGoogle Scholar
  98. Kim D, Lee ES, Oh KT, Gao ZG, Bae YH (2008) Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small 4:2043–2050PubMedCentralPubMedGoogle Scholar
  99. Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, Park K, Lee MY, Heo DS (2007a) Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 18:2009–2014PubMedGoogle Scholar
  100. Kim JS, Rieter WJ, Taylor KM, An H, Lin W, Lin W (2007b) Self-assembled hybrid nanoparticles for cancer-specific multimodal imaging. J Am Chem Soc 129:8962–8963PubMedCentralPubMedGoogle Scholar
  101. Kim K, Lee M, Park H, Kim JH, Kim S, Chung H, Choi K, Kim IS, Seong BL, Kwon IC (2006) Cell-permeable and biocompatible polymeric nanoparticles for apoptosis imaging. J Am Chem Soc 128:3490–3491PubMedGoogle Scholar
  102. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, Seo MH (2001) In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 72: 191–202PubMedGoogle Scholar
  103. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ (2004) Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10:3708–3716PubMedGoogle Scholar
  104. Klibanov AL, Maruyama K, Torchilin VP, Huang L (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268:235–237PubMedGoogle Scholar
  105. Kocer A (2007) A remote controlled valve in liposomes for triggered liposomal release. J Liposome Res 17:219–225PubMedGoogle Scholar
  106. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, Balogh LP, Khan MK, Baker JR Jr (2005) Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 65:5317–5324PubMedGoogle Scholar
  107. Langer R (1998) Drug delivery and targeting. Nature 392:5–10PubMedGoogle Scholar
  108. Langer R, Folkman J (1976) Polymers for the sustained release of proteins and other macromolecules. Nature 263:797–800PubMedGoogle Scholar
  109. Lanza G, Winter P, Cyrus T, Caruthers S, Marsh J, Hughes M, Wickline S (2006) Nanomedicine opportunities in cardiology. Ann N Y Acad Sci 1080:451–465PubMedGoogle Scholar
  110. Lee CC, MacKay JA, Frechet JM, Szoka FC (2005) Designing dendrimers for biological applications. Nat Biotechnol 23:1517–1526PubMedGoogle Scholar
  111. Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, Rha SY, Lee MY, Ro J (2008) Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 108:241–250PubMedGoogle Scholar
  112. Leserman LD, Barbet J, Kourilsky F, Weinstein JN (1980) Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature 288:602–604PubMedGoogle Scholar
  113. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC (2008) Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol 26:442–449PubMedGoogle Scholar
  114. Li C (2002) Poly(L-glutamic acid)–anticancer drug conjugates. Adv Drug Deliv Rev 54:695–713PubMedGoogle Scholar
  115. Li C, Wallace S (2008) Polymer–drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev 60:886–898PubMedCentralPubMedGoogle Scholar
  116. Li SD, Huang L (2008a) Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 5:496–504PubMedGoogle Scholar
  117. Li SD, Huang L (2008b) Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. Curr Opin Investig Drugs 9:1317–1323PubMedGoogle Scholar
  118. Liggins RT, Burt HM (2002) Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations. Adv Drug Deliv Rev 54:191–202PubMedGoogle Scholar
  119. Lindman S, Lynch I, Thulin E, Nilsson H, Dawson KA, Linse S (2007) Systematic investigation of the thermodynamics of HSA adsorption to N-iso-propylacrylamide/N-tert-butylacrylamide copolymer nanoparticles. Effects of particle size and hydrophobicity. Nano Lett 7:914–920PubMedGoogle Scholar
  120. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA (2008) Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA 105:14265–14270PubMedGoogle Scholar
  121. Luten J, van Nostrum CF, De Smedt SC, Hennink WE (2008) Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J Control Release 126:97–110PubMedGoogle Scholar
  122. MacDiarmid JA, Mugridge NB, Weiss JC, Phillips L, Burn AL, Paulin RP, Haasdyk JE, Dickson KA, Brahmbhatt VN, Pattison ST, James AC, Al Bakri G, Straw RC, Stillman B, Graham RM, Brahmbhatt H (2007) Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 11:431–445PubMedGoogle Scholar
  123. Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189–207PubMedGoogle Scholar
  124. Majoros IJ, Myc A, Thomas T, Mehta CB, Baker JR Jr (2006) PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 7:572–579PubMedGoogle Scholar
  125. Majoros IJ, Thomas TP, Mehta CB, Baker JR Jr (2005) Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J Med Chem 48:5892–5899PubMedGoogle Scholar
  126. Matsumura Y (2008) Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv Drug Deliv Rev 60:899–914PubMedGoogle Scholar
  127. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M, Watanabe N (2004) Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 91:1775–1781PubMedCentralPubMedGoogle Scholar
  128. McCarthy JR, Weissleder R (2008) Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 60:1241–1251PubMedCentralPubMedGoogle Scholar
  129. McCarthy TD, Karellas P, Henderson SA, Giannis M, O'Keefe DF, Heery G, Paull JR, Matthews BR, Holan G (2005) Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm 2:312–318PubMedGoogle Scholar
  130. Minko T, Kopeckova P, Pozharov V, Jensen KD, Kopecek J (2000) The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors. Pharm Res 17:505–514PubMedGoogle Scholar
  131. Moghimi SM (2006) Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology. Anticancer Agents Med Chem 6:553–561PubMedGoogle Scholar
  132. Moghimi SM, Hunter AC, Murray JC (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53:283–318PubMedGoogle Scholar
  133. Moghimi SM, Hunter AC, Murray JC (2005) Nanomedicine: current status and future prospects. Faseb J 19:311–330PubMedGoogle Scholar
  134. Montet X, Weissleder R, Josephson L (2006) Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas. Bioconjug Chem 17:905–911PubMedGoogle Scholar
  135. Morgan TT, Muddana HS, Altinoglu EI, Rouse SM, Tabakovic A, Tabouillot T, Russin TJ, Shanmugavelandy SS, Butler PJ, Eklund PC, Yun JK, Kester M, Adair JH (2008) Encapsulation of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery. Nano Lett 8(12):4108–4115PubMedCentralPubMedGoogle Scholar
  136. Murakami T, Tsuchida K (2008) Recent advances in inorganic nanoparticle-based drug delivery systems. Mini Rev Med Chem 8:175–183PubMedGoogle Scholar
  137. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, Wrasidlo W, Cheresh DA (2008) Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 105:9343–9348PubMedGoogle Scholar
  138. Myc A, Douce TB, Ahuja N, Kotlyar A, Kukowska-Latallo J, Thomas TP, Baker JR Jr (2008) Preclinical antitumor efficacy evaluation of dendrimer-based methotrexate conjugates. Anticancer Drugs 19:143–149PubMedGoogle Scholar
  139. Najlah M, D'Emanuele A (2007) Synthesis of dendrimers and drug-dendrimer conjugates for drug delivery. Curr Opin Drug Discov Devel 10:756–767PubMedGoogle Scholar
  140. Nasongkla N, Bey E, Ren J, Ai H, Khemtong C, Guthi JS, Chin SF, Sherry AD, Boothman DA, Gao J (2006) Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett 6:2427–2430PubMedGoogle Scholar
  141. Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD (2005) Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23:7785–7793PubMedGoogle Scholar
  142. Overall CM, Kleifeld O (2006) Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6:227–239PubMedGoogle Scholar
  143. Paciotti GF, Myer L, Weinreich D, Goia D, Pavel N, McLaughlin RE, Tamarkin L (2004) Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 11:169–183PubMedGoogle Scholar
  144. Park H, Yang J, Seo S, Kim K, Suh J, Kim D, Haam S, Yoo KH (2008) Multifunctional nanoparticles for photothermally controlled drug delivery and magnetic resonance imaging enhancement. Small 4:192–196PubMedGoogle Scholar
  145. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760PubMedGoogle Scholar
  146. Peppas NA (2004) Intelligent therapeutics: biomimetic systems and nanotechnology in drug delivery. Adv Drug Deliv Rev 56:1529–1531PubMedGoogle Scholar
  147. Peracchia MT, Harnisch S, Pinto-Alphandary H, Gulik A, Dedieu JC, Desmaele D, d'Angelo J, Muller RH, Couvreur P (1999) Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials 20:1269–1275PubMedGoogle Scholar
  148. Porche DJ (1996) Liposomal doxorubicin (Doxil). J Assoc Nurses AIDS Care 7:55–59PubMedGoogle Scholar
  149. Posey JA 3rd, Saif MW, Carlisle R, Goetz A, Rizzo J, Stevenson S, Rudoltz MS, Kwiatek J, Simmons P, Rowinsky EK, Takimoto CH, Tolcher AW (2005) Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas. Clin Cancer Res 11:7866–7871PubMedGoogle Scholar
  150. Pridgen EM, Langer R, Farokhzad OC (2007) Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomed 2:669–680Google Scholar
  151. Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I, Patri AK, Thomas T, Mule J, Baker JR Jr (2002) Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 19:1310–1316PubMedGoogle Scholar
  152. Rapoport N, Gao Z, Kennedy A (2007) Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst 99:1095–1106PubMedGoogle Scholar
  153. Rice JR, Gerberich JL, Nowotnik DP, Howell SB (2006) Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res 12:2248–2254PubMedGoogle Scholar
  154. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H (2009) Nanomedicine–challenge and perspectives. Angew Chem Int Ed Engl 48:872–897PubMedGoogle Scholar
  155. Rolland JP, Maynor BW, Euliss LE, Exner AE, Denison GM, DeSimone JM (2005) Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J Am Chem Soc 127:10096–10100PubMedGoogle Scholar
  156. Rosen H, Abribat T (2005) The rise and rise of drug delivery. Nat Rev Drug Discov 4:381–385PubMedGoogle Scholar
  157. Salvador-Morales C, Gao W, Ghatalia P, Murshed F, Aizu W, Langer R, Farokhzad OC (2009a) Multifunctional nanoparticles for prostate cancer therapy. Expert Rev Anticancer Ther 9:211–221PubMedGoogle Scholar
  158. Salvador-Morales C, Zhang L, Langer R, Farokhzad OC (2009b) Immunocompatibility properties of lipid–polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 30:2231–2240PubMedCentralPubMedGoogle Scholar
  159. Sawaki A, Yamao K (2004) Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors–a review. Cancer Chemother Pharmacol 54(Suppl 1): S44–S49PubMedGoogle Scholar
  160. Schneider GF, Subr V, Ulbrich K, Decher G (2009) Multifunctional cytotoxic stealth nanoparticles. A model approach with potential for cancer therapy. Nano Lett 9:636–642PubMedGoogle Scholar
  161. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5:147–159PubMedGoogle Scholar
  162. Schwartz JA, Shetty AM, Price RE, Stafford RJ, Wang JC, Uthamanthil RK, Pham K, McNichols RJ, Coleman CL, Payne JD (2009) Feasibility study of particle-assisted laser ablation of brain tumors in orthotopic canine model. Cancer Res 69:1659–1667PubMedGoogle Scholar
  163. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R (2005) Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436:568–572PubMedGoogle Scholar
  164. Shin J, Anisur RM, Ko MK, Im GH, Lee JH, Lee IS (2009) Hollow manganese oxide nanoparticles as multifunctional agents for magnetic resonance imaging and drug delivery. Angew Chem Int Ed Engl 48:321–324PubMedGoogle Scholar
  165. Siclari VA, Guise TA, Chirgwin JM (2006) Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev 25:621–633PubMedGoogle Scholar
  166. Singer JW (2005) Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane. J Control Release 109:120–126PubMedGoogle Scholar
  167. Singer JW, Baker B, De Vries P, Kumar A, Shaffer S, Vawter E, Bolton M, Garzone P (2003) Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv Exp Med Biol 519:81–99PubMedGoogle Scholar
  168. Sinha R, Kim GJ, Nie S, Shin DM (2006) Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 5:1909–1917PubMedGoogle Scholar
  169. Soepenberg O, de Jonge MJ, Sparreboom A, de Bruin P, Eskens FA, de Heus G, Wanders J, Cheverton P, Ducharme MP, Verweij J (2005) Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin Cancer Res 11:703–711PubMedGoogle Scholar
  170. Sood P, Thurmond KB 2nd, Jacob JE, Waller LK, Silva GO, Stewart DR, Nowotnik DP (2006) Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent. Bioconjug Chem 17:1270–1279PubMedGoogle Scholar
  171. Strebhardt K, Ullrich A (2008) Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 8:473–480PubMedGoogle Scholar
  172. Sudimack J, Lee RJ (2000) Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 41:147–162PubMedGoogle Scholar
  173. Sudimack JJ, Guo W, Tjarks W, Lee RJ (2002) A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim Biophys Acta 1564:31–37PubMedGoogle Scholar
  174. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219–234PubMedGoogle Scholar
  175. Tejada-Berges T, Granai CO, Gordinier M, Gajewski W (2002) Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev Anticancer Ther 2:143–150PubMedGoogle Scholar
  176. Thanou M, Duncan R (2003) Polymer–protein and polymer–drug conjugates in cancer therapy. Curr Opin Investig Drugs 4:701–709PubMedGoogle Scholar
  177. Thevenot J, Troutier AL, David L, Delair T, Ladaviere C (2007) Steric stabilization of lipid/polymer particle assemblies by poly(ethylene glycol)-lipids. Biomacromolecules 8:3651–3660PubMedGoogle Scholar
  178. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–160PubMedGoogle Scholar
  179. Tribler L, Jensen LT, Jorgensen K, Brunner N, Gelb MH, Nielsen HJ, Jensen SS (2007) Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue. Anticancer Res 27:3179–3185PubMedGoogle Scholar
  180. Tseng YC, Mozumdar S, Huang L (2009) Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev 61:721–731PubMedCentralPubMedGoogle Scholar
  181. Tsukioka Y, Matsumura Y, Hamaguchi T, Koike H, Moriyasu F, Kakizoe T (2002) Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil). Jpn J Cancer Res 93:1145–1153PubMedGoogle Scholar
  182. Uchegbu IF (2006) Pharmaceutical nanotechnology: polymeric vesicles for drug and gene delivery. Expert Opin Drug Deliv 3:629–640PubMedGoogle Scholar
  183. Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T (2005) Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 93:678–687PubMedCentralPubMedGoogle Scholar
  184. van Vlerken LE, Amiji MM (2006) Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin Drug Deliv 3:205–216PubMedGoogle Scholar
  185. van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM (2008) Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Mol Pharm 5:516–526PubMedCentralPubMedGoogle Scholar
  186. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J (1999) Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 5:83–94PubMedGoogle Scholar
  187. Venugopal J, Prabhakaran MP, Low S, Choon AT, Zhang YZ, Deepika G, Ramakrishna S (2008) Nanotechnology for nanomedicine and delivery of drugs. Curr Pharm Des 14:2184–2200PubMedGoogle Scholar
  188. Verma A, Uzun O, Hu Y, Hu Y, Han HS, Watson N, Chen S, Irvine DJ, Stellacci F (2008) Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat Mater 7:588–595PubMedCentralPubMedGoogle Scholar
  189. Vial F, Rabhi S, Tribet C (2005) Association of octyl-modified poly(acrylic acid) onto unilamellar vesicles of lipids and kinetics of vesicle disruption. Langmuir 21:853–862PubMedGoogle Scholar
  190. Visaria R, Bischof JC, Loren M, Williams B, Ebbini E, Paciotti G, Griffin R (2007) Nanotherapeutics for enhancing thermal therapy of cancer. Int J Hyperthermia 23:501–511PubMedGoogle Scholar
  191. Visaria RK, Griffin RJ, Williams BW, Ebbini ES, Paciotti GF, Song CW, Bischof JC (2006) Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-alpha delivery. Mol Cancer Ther 5:1014–1020PubMedGoogle Scholar
  192. Wang AZ, Gu F, Zhang L, Chan JM, Radovic-Moreno A, Shaikh MR, Farokhzad OC (2008a) Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther 8:1063–1070PubMedCentralPubMedGoogle Scholar
  193. Wang G, Uludag H (2008) Recent developments in nanoparticle-based drug delivery and targeting systems with emphasis on protein-based nanoparticles. Expert Opin Drug Deliv 5:499–515PubMedGoogle Scholar
  194. Wang L, Bai J, Li Y, Huang Y (2008b) Multifunctional nanoparticles displaying magnetization and near-IR absorption. Angew Chem Int Ed Engl 47:2439–2442PubMedGoogle Scholar
  195. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8:129–138PubMedGoogle Scholar
  196. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY (2007) Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 59:491–504PubMedGoogle Scholar
  197. Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY (2006a) A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer–lipid hybrid nanoparticle system. J Pharmacol Exp Ther 317:1372–1381PubMedGoogle Scholar
  198. Wong HL, Rauth AM, Bendayan R, Manias JL, Ramaswamy M, Liu Z, Erhan SZ, Wu XY (2006b) A new polymer–lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res 23:1574–1585PubMedGoogle Scholar
  199. Zamboni WC (2008) Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 13:248–260PubMedGoogle Scholar
  200. Zetter BR (2008) The scientific contributions of M. Judah Folkman to cancer research. Nat Rev Cancer 8:647–654PubMedGoogle Scholar
  201. Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ, Radovic-Moreno AF, Alexis F, Langer R, Farokhzad OC (2008a) Self-assembled lipid–polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2:1696–1702PubMedGoogle Scholar
  202. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC (2008b) Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83:761–769PubMedGoogle Scholar
  203. Zhang L, Radovic-Moreno AF, Alexis F, Gu FX, Basto PA, Bagalkot V, Jon S, Langer RS, Farokhzad OC (2007) Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2:1268–1271PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Frank Alexis
  • Eric M. Pridgen
  • Robert Langer
  • Omid C. Farokhzad
    • 1
  1. 1.Harvard Medical School, Laboratory of Nanomedicine and BiomaterialsBrigham and Women’s HospitalBostonUSA

Personalised recommendations